ArticleEuropean heart journal. Quality of care & clinical outcomes2019
Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data.
Article in European heart journal. Quality of care & clinical outcomes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies.PloS one · 2022Pooled it
- Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness.PharmacoEconomics · 2020Pooled it
- Systemic inflammation is associated with increased risk of death in population with atherosclerotic cardiovascular disease and chronic kidney disease-a Danish national register study.Frontiers in cardiovascular medicine · 2026Article
- Risk Factor Assessments and Lipid Management Patterns in Hospitalised Patients in Malaysia: The Atherosclerotic Cardiovascular Disease Study.The Malaysian journal of medical sciences : MJMS · 2025Article
- Low KV-low contrast medium dose one-stop dual source CT high pitch integrated coronary-carotid-cerebral-aortic CTA improves image quality and reduces both radiation and contrast medium doses.European journal of radiology open · 2025Article
- Lipid-lowering prescription patterns after a non-fatal acute coronary syndrome: A retrospective cohort study.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- The Polypill (Acetyl Salicylic Acid, Atorvastatin, and Ramipril) Paradigm Shift in Secondary Prevention: Global Expert Delphi Consensus.Global heart · 2025Article
- Risk stratification for cardiovascular disease based on prior coronary artery disease, cerebrovascular disease and type 2 diabetes mellitus.Journal of diabetes investigation · 2024Article
- Review
- Patients' health care resources utilization and costs estimation across cardiovascular risk categories: insights from the LATINO study.Health economics review · 2024Article
- Real-World Risk of Recurrent Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with LDL-C Above Guideline-Recommended Threshold: A Retrospective Observational Study.Cardiology and therapy · 2024Article
- Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain.Frontiers in cardiovascular medicine · 2024Article
- Economic burden of atherosclerotic cardiovascular disease: a matched case-control study in more than 450,000 Swedish individuals.BMC cardiovascular disorders · 2023Article
- Novel Insights into the Molecular Mechanisms of Atherosclerosis.International journal of molecular sciences · 2023Review
- Prognostic value of triglyceride glucose index in population at high cardiovascular disease risk.Cardiovascular diabetology · 2023Article
- Article
- Article
- Analysis of Anti-Arrhythmic Impacts of Crocin through Estimation of Expression of Cx43 in Myocardial Infarction Using a Rat Animal Model.ACS omega · 2022Article
- Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada.Advances in therapy · 2022Article
- Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study.European heart journal. Quality of care & clinical outcomes · 2022Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study aimed to estimate the rate of cardiovascular (CV) events in the real world in patients at high risk of recurrent CV events similar to the FOURIER trial population. METHODS AND
resultsA retrospective population-based cohort study was conducted using Swedish national registers from 1 July 2001 to 31 December 2015. Patients in the atherosclerotic cardiovascular disease (ASCVD) prevalent cohort met the FOURIER-like inclusion criteria, including treatment with high/moderate-intensity statins, on 1 July 2006. Additionally, two cohorts defined by diagnosis of incident ischaemic stroke (IS) and incident myocardial infarction (MI), meeting the FOURIER-like inclusion criteria were followed from date of diagnosis. Event rates were calculated for the hard major adverse cardiovascular events (MACE) composite: MI, IS, and CV death; and the ASCVD composite: MI, IS, unstable angina, coronary revascularization, and CV death. Approximately half of patients experienced a CV event (ASCVD composite) during follow-up. The MACE composite rates/100 person-years were 6.3, 11.9, and 12.3 in the ASCVD prevalent (n = 54 992), MI incident (n = 45 895), and IS incident (n = 36 134) cohorts, respectively. The ASCVD composite rates/100 person-years were 7.0, 21.7, and 12.9 in the ASCVD prevalent, MI incident, and IS incident cohorts, respectively. The multiple-event MACE composite rates/100 person-years were 8.5 (ASCVD prevalent cohort), 15.4 (MI incident cohort), and 14.4 (IS incident cohort).
conclusionIn this real-world setting, CV event rates were high in all studied cohorts. In particular, the MACE composite rates were two to three times higher than in the FOURIER clinical trial, indicating a substantial disease burden despite treatment with moderate or high-intensity statins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.